High Throughput Immunoassay for Flagellin

鞭毛蛋白的高通量免疫分析

• 批准号: 8516169
• 负责人: MARTIN D. CHAPMAN
• 金额: $ 18.43万
• 依托单位: INDOOR BIOTECHNOLOGIES
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-15 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8516169
• 关键词: Academia; Accounting; Adjuvant; Admission activity; Affect; Affinity; Allergens; Allergic; Allergic Disease; Animals; Antibodies; Asthma; Atopic Dermatitis; Bacteria; Bacterial Proteins; Biological Assay; Biological Markers; Biotechnology; Canis familiaris; Centers for Disease Control and Prevention (U.S.); Child; Childhood; Chronic Disease; Collaborations; Communicable Diseases; Complement; Detection; Development; Dictyoptera; Disease; Dose; Dust; Endotoxins; Environmental Exposure; Environmental Monitoring; Enzyme-Linked Immunosorbent Assay; Europe; Exclusion; Exposure to; Family; Farming environment; Felis catus; Flagella; Flagellin; Genetic; Goals; Government Agencies; Hay fever; High Pressure Liquid Chromatography; Home environment; Hospitalization; Hospitals; House Dust; Household; Housing; Human; Hypersensitivity; Immune response; Immunoassay; Immunoblotting; Immunology; Infectious Disease Immunology; Investigation; Ion Exchange; Life; Link; Low Prevalence; Manufacturer Name; Marketing; Measurement; Measures; Molds; Molecular Weight; Monoclonal Antibodies; Mus; National Institute of Environmental Health Sciences; Natural Immunity; Oryctolagus cuniculus; Patients; Performance; Pharmacologic Substance; Phase; Precipitation; Production; Proteins; Pseudomonas aeruginosa; Public Health; Reagent; Recombinants; Reproducibility; Research; Research Personnel; Risk Factors; Role; Sampling; Sensitivity and Specificity; Services; Site; Small Business Innovation Research Grant; Socioeconomic Status; Sodium Chloride; Standardization; Suspension substance; Suspensions; System; Techniques; Testing; Toll-Like Receptor 5; Ultrafiltration; Vaccines; air sampling; allergic response; base; commercialization; cooking; early childhood; economic cost; environmental allergen; mouse model; polyclonal antibody; protective effect; public health relevance; pyroglyphid; research study; respiratory; response; tool

DESCRIPTION (provided by applicant): Asthma is a serious public health problem in the US that affects one in ten schoolchildren and causes ~500,000 hospitalizations each year, with an estimated economic cost of $56 billion. Allergic sensitization to household allergens (dust mites, cat, dog, mouse, cockroach, molds) is a major risk factor for the development of asthma. Asthma in early childhood can also be influenced by exposure to bacterial products which may potentiate or have protective effects depending on the level of environmental exposure and genetic factors. Recent studies in a mouse model have shown that the bacterial protein, flagellin, promotes allergic sensitization to indoor allergens and that human patients with asthma have high levels of antibodies to flagellin. Household dust samples have been shown to contain flagellin. However, investigation of the association between exposure to flagellin and asthma requires a robust test to measure flagellin in environmental samples from homes and public buildings. The goal of this SBIR Phase I project is to develop a high throughput immunoassay for flagellin, capable of analyzing several hundred samples per week. The specific aims of the project are i) to purify flagellin from Pseudomonas aeruginosa; ii) to develop a monoclonal or polyclonal antibody based immunoassay which detects flagellin from most bacterial species; iii) to validate the assay performance to measure flagellin in dust samples of known allergen and endotoxin content. The strategy involves developing a multiplexed immunoassay which can be used to measure flagellin, allergens and molds simultaneously. This assay will be to assess the role of flagellin exposure in allergic disease. Commercial potential: Successful completion of this SBIR will result in valuable immunoassay product(s) that can be marketed by the applicant, Indoor Biotechnologies, to allergy/immunology researchers in academia, government agencies, pharmaceutical companies and vaccine manufacturers, worldwide. The research could generate several product lines that are complementary to the company's current products and which will enable the company to expand its product range in new markets.

描述（由申请人提供）：在美国，哮喘是一个严重的公共卫生问题，影响十分之一的学童，每年造成约500,000个住院治疗，估计经济成本为560亿美元。对家用过敏原（尘螨，猫，狗，小鼠，蟑螂，模具）的过敏性敏化是哮喘发展的主要危险因素。幼儿期的哮喘也可能受到暴露于细菌产物的影响，这些细菌产物可能会增强或根据环境暴露和遗传因素的水平增强或具有保护作用。小鼠模型中的最新研究表明，细菌蛋白鞭毛蛋白促进对室内过敏原的过敏性致敏，并且哮喘患者的患者对鞭毛蛋白具有高水平的抗体。已显示家庭灰尘样品包含鞭毛蛋白。但是，对暴露于鞭毛蛋白和哮喘之间的关联的调查需要一项可靠的测试，以测量房屋和公共建筑物环境样本中的鞭毛蛋白。该SBIR I期项目的目标是为鞭毛蛋白开发高通量免疫测定法，每周能够分析数百个样本。该项目的具体目的是i）从铜绿假单胞菌中净化鞭毛蛋白； ii）开发基于单克隆或多克隆抗体的免疫测定法，该免疫测定检测大多数细菌物种的鞭毛蛋白； iii）验证测定性能以测量已知过敏原和内毒素含量的灰尘样品中的鞭毛蛋白。该策略涉及开发多重免疫测定法，可同时测量鞭毛蛋白，过敏原和霉菌。该测定方法是评估鞭毛蛋白暴露在过敏性疾病中的作用。商业潜力：成功完成 SBIR将产生有价值的免疫测定产品，可以由申请人，室内生物技术向学术界，政府机构，制药公司和疫苗制造商（全球）销售给室内生物技术。这项研究可能会生成几种与公司当前产品互补的产品线，这将使公司能够在新市场中扩大其产品范围。